1.94
0.09 (4.86%)
| 前收盘价格 | 1.85 |
| 收盘价格 | 1.91 |
| 成交量 | 320,762 |
| 平均成交量 (3个月) | 49,850 |
| 市值 | 18,025,898 |
| 股市价格/股市净资产 (P/B) | 0.790 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -11,193.25% |
| 稀释每股收益 (EPS TTM) | -3.70 |
| 季度收入增长率 (YOY) | -62.40% |
| 总债务/股东权益 (D/E MRQ) | 31.69% |
| 流动比率 (MRQ) | 1.69 |
| 营业现金流 (OCF TTM) | -31.34 M |
| 杠杆自由现金流 (LFCF TTM) | -19.08 M |
| 资产报酬率 (ROA TTM) | -48.28% |
| 股东权益报酬率 (ROE TTM) | -92.35% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | SAB Biotherapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 1.00 |
|
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 15.96% |
| 机构持股比例 | 23.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| First Premier Bank | 31 Dec 2024 | 18,986 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (Chardan Capital, 930.93%) | 购买 |
| 中 | 15.00 (673.20%) | |
| 低 | 10.00 (HC Wainwright & Co., 415.46%) | 购买 |
| 平均值 | 15.00 (673.20%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.90 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 15 May 2025 | 20.00 (930.93%) | 购买 | 1.94 |
| 01 Apr 2025 | 20.00 (930.93%) | 购买 | 1.23 | |
| HC Wainwright & Co. | 14 May 2025 | 10.00 (415.46%) | 购买 | 1.85 |
| 01 Apr 2025 | 6.00 (209.28%) | 购买 | 1.23 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 09 May 2025 | 公告 | SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates |
| 31 Mar 2025 | 公告 | SAB BIO Reports Full Year 2024 Operating and Financial Results |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合